Novel four-way Ph translocation t(9;22;7;1)(q34;q11;q22;p13) in a chronic myeloid leukemia patient receiving tyrosine kinase inhibitor therapy.
The occurrence of a four-way Philadelphia chromosome translocation is a very rare event in myeloid malignancies, and the phenotypic consequences of such rearrangements remain to be investigated. We describe a case of a chronic myeloid leukemia (CML) patient with a complex four-way t(9;22;7,1) translocation who received multiple tyrosine kinase inhibitor therapy. As evaluation of prognostic features in a limited number of patients with four-way Philadelphia rearrangements at present yields controversial results, our case may add further information on the prognostic impact of such abnormalities in CML patients receiving tyrosine kinase inhibitor therapy, and may help delineate a sub-group of patients requiring different therapeutic approaches.
Laboratory of Cancer Genetics, Department of Hematology, Kuwait Cancer Control Center, PO Box 42262, 70653 Kuwait, Kuwait. annaadria@yahoo.com
Zámečníkova
Z
Adriana
Soad
S
Al Bahar
D002871:Chromosome Banding; D002878:Chromosomes, Human, Pair 1; D002892:Chromosomes, Human, Pair 22; D002897:Chromosomes, Human, Pair 7; D002899:Chromosomes, Human, Pair 9; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D014178:Translocation, Genetic; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors